I
INBX
Inhibrx Biosciences Inc
62.35
-1.37-2.15%Closed18:48 04/07 EDT
OPEN/PREV CLOSE62.90/63.72
TODAY RANGE60.33-63.69
VOL142.46K
MARKET CAP910.75M
52 WEEK RANGE10.81-94.57
AVG VOL (3M)198.04K
% TURNOVER0.98%
TURNOVER0
P/E (TTM)-6.8945
% RANGE5.28%
EPS(TTM)-9.0434
P/E(FORWARD)-11.4194
P/B113.72
BVPS0.5483
DIVIDEND--
P/S698.99
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP572.23M
SHARES OUTSTANDING14.61M
NEXT EARNINGS05/12-05/18
FREE FLOAT9.18M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·12h ago
Inhibrx initiated with a Buy at Stifel
Seeking Alpha·03/25 13:05
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data
Reuters·03/19 20:09
Inhibrx Biosciences Q4 net loss narrows as expenses fall
Seeking Alpha·03/19 20:01
Inhibrx Biosciences GAAP EPS of -$2.11 misses by $0.03
Reuters·03/19 20:00
INHIBRX Q4 EPS USD -2.11
Reuters·03/19 20:00
INHIBRX REPORTS FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS
PR Newswire·03/02 21:00
Inhibrx Announces Participation in Upcoming Scientific Conference
TipRanks·02/23 14:33
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy
Seeking Alpha·01/13 20:09
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too
Simply Wall St·12/18/2025 05:18
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates
TipRanks·12/16/2025 22:39
Inhibrx Biosciences Updates on Clinical Trials Progress
TipRanks·12/16/2025 22:10
Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial
Reuters·12/16/2025 22:00
Inhibrx Biosciences Advances INBRX-106 Phase 2/3 Trial for Head and Neck Cancer
Same Industry
Name/Symbol
Change%
Price